共 73 条
iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition
被引:28
作者:
Chen, Shuo
[1
]
Wu, Jiale
[2
]
Zhong, Shan
[1
]
Li, Yuntong
[2
]
Zhang, Ping
[1
]
Ma, Jingyi
[1
]
Ren, Jingshan
[3
]
Tan, Yun
[2
]
Wang, Yunhao
[4
]
Au, Kin Fai
[4
,5
]
Siebold, Christian
[3
]
Bond, Gareth L.
[1
]
Chen, Zhu
[2
]
Lu, Min
[2
]
Jones, E. Yvonne
[3
]
Lu, Xin
[1
]
机构:
[1] Univ Oxford, Nuffield Dept Med, Ludwig Canc Res, Oxford OX3 7DQ, England
[2] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, State Key Lab Med Genom,Shanghai Inst Hematol, Shanghai 200025, Peoples R China
[3] Univ Oxford, Wellcome Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England
[4] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[5] Univ Iowa, Dept Biostat, Iowa City, IA 52242 USA
来源:
基金:
欧洲研究理事会;
国家重点研发计划;
英国惠康基金;
中国国家自然科学基金;
关键词:
p53;
iASPP;
crystal structure;
target selectivity;
HPV E6;
CELL-CYCLE ARREST;
CRYSTAL-STRUCTURE;
STRUCTURAL BASIS;
CORE DOMAIN;
TRANSCRIPTION FACTORS;
MUTATIONAL LANDSCAPE;
APOPTOTIC FUNCTION;
BINDING DOMAIN;
ASPP;
PROTEINS;
D O I:
10.1073/pnas.1909393116
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
The most frequently mutated protein in human cancer is p53, a transcription factor (TF) that regulates myriad genes instrumental in diverse cellular outcomes including growth arrest and cell death. Cell context-dependent p53 modulation is critical for this life-or-death balance, yet remains incompletely understood. Here we identify sequence signatures enriched in genomic p53-binding sites modulated by the transcription cofactor iASPP. Moreover, our p53-iASPP crystal structure reveals that iASPP displaces the p53 L1 loop-which mediates sequence-specific interactions with the signature-corresponding base-without perturbing other DNA-recognizing modules of the p53 DNA-binding domain. A TF commonly uses multiple structural modules to recognize its cognate DNA, and thus this mechanism of a cofactor fine-tuning TF-DNA interactions through targeting a particular module is likely widespread. Previously, all tumor suppressors and oncoproteins that associate with the p53 DNA-binding domain-except the oncogenic E6 from human papillomaviruses (HPV5)-structurally cluster at the DNA-binding site of p53, complicating drug design. By contrast, iASPP inhibits p53 through a distinct surface overlapping the E6 footprint, opening prospects for p53-targeting precision medicine to improve cancer therapy.
引用
收藏
页码:17470 / 17479
页数:10
相关论文